Unraveling the therapeutic mechanisms of placenta hominis for polycystic ovary syndrome through network pharmacology, molecular docking, and experimental validation
- 1The First Clinical School of Medicine, Guangzhou University of Chinese Medicine
- 2Department of Medical Ultrasonics, Institute of Diagnostic and Interventional Ultrasound, The First Affiliated Hospital of Sun Yat-Sen University
- 3The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Abstract
This study employed an integrated strategy of network pharmacology, molecular docking, and in vitro assays in KGN cells to explore the mechanisms of action of Placenta Hominis (PH) in Polycystic Ovary Syndrome (PCOS). We hypothesized that PH (which contains bioactive compounds such as steroid hormones and peptides) exerts its therapeutic effects against PCOS through a multi-target mechanism. Potential targets of PH- and PCOS-related genes were identified in public databases. After network analysis and filtering by interaction confidence scores, 289 common targets were retained. Subsequent protein-protein interaction (PPI) analysis identified 30 core targets, including sex hormone-related (AR, ESR1, INS) and apoptosis-related (TP53, TNF, NFκB1, BCL2) proteins. Enrichment analyses (GO and KEGG) suggested that PH may exert therapeutic effects primarily through pathways such as endocrine resistance and estrogen signaling. Molecular docking suggested stable binding between key PH compounds and the core targets, and molecular dynamics simulations supported stable binding between progesterone and the apoptosis-related proteins (TP53, TNF, NFκB1, BCL2). In cellular experiments using DHT-induced KGN cells, PH treatment promoted proliferation, reduced oxidative stress, and suppressed apoptosis compared to the DHT only control. Mechanistically, these effects involved the modulation of sex hormone- and apoptosis-related pathways. In conclusion, this multi-method study demonstrates that PH can mitigate PCOS progression by regulating central pathways linked to hormonal balance and apoptosis, providing a theoretical basis for future preclinical in vivo studies and further investigation into potential clinical applications.
Related
- Unraveling the multitarget mechanisms of aloe emodin against periodontitis: a synergy of network pharmacology and experimental validation
- Study on the Active Constituents and Underlying Mechanisms of Renshen Yangying Decoction Against Angina Pectoris Based on Integrated Serum Pharmacochemistry, Network Pharmacology, Molecular Docking, and Experimental Validation
- Network pharmacology and experimental validation reveal the anti-inflammatory mechanisms of andrographolide in the treatment of periodontitis.
- Chinese herbal medicine for recurrent urinary tract infection: formulation-specific clinical evidence, experimental pharmacology, and unresolved recurrence mechanisms
- Exploring the potential mechanisms of Pei Yuan Yi Fei decoction for non-small cell lung cancer through network pharmacology and experimental validation
BibTeX
@article{pan2026unraveling,
title = {{Unraveling the therapeutic mechanisms of placenta hominis for polycystic ovary syndrome through network pharmacology, molecular docking, and experimental validation}},
author = {Haixia Pan and Meilin Wu and Ting Mao and Ziyi Deng and Yingqiao Zhong and Yong Guo and Siyang Chen and Lei Huang and Daopeng Yang and Ying Zhou},
journal = {Scientific Reports},
year = {2026},
month = jul,
doi = {10.1038/s41598-026-60535-5},
url = {https://doi.org/10.1038/s41598-026-60535-5},
note = {CC BY},
}
RIS
TY - JOUR
TI - Unraveling the therapeutic mechanisms of placenta hominis for polycystic ovary syndrome through network pharmacology, molecular docking, and experimental validation
AU - Haixia Pan
AU - Meilin Wu
AU - Ting Mao
AU - Ziyi Deng
AU - Yingqiao Zhong
AU - Yong Guo
AU - Siyang Chen
AU - Lei Huang
AU - Daopeng Yang
AU - Ying Zhou
PY - 2026
DA - 2026/07/01
JO - Scientific Reports
DO - 10.1038/s41598-026-60535-5
UR - https://doi.org/10.1038/s41598-026-60535-5
AB - This study employed an integrated strategy of network pharmacology, molecular docking, and in vitro assays in KGN cells to explore the mechanisms of action of Placenta Hominis (PH) in Polycystic Ovary Syndrome (PCOS). We hypothesized that PH (which contains bioactive compounds such as steroid hormones and peptides) exerts its therapeutic effects against PCOS through a multi-target mechanism. Potential targets of PH- and PCOS-related genes were identified in public databases. After network analysis and filtering by interaction confidence scores, 289 common targets were retained. Subsequent protein-protein interaction (PPI) analysis identified 30 core targets, including sex hormone-related (AR, ESR1, INS) and apoptosis-related (TP53, TNF, NFκB1, BCL2) proteins. Enrichment analyses (GO and KEGG) suggested that PH may exert therapeutic effects primarily through pathways such as endocrine resistance and estrogen signaling. Molecular docking suggested stable binding between key PH compounds and the core targets, and molecular dynamics simulations supported stable binding between progesterone and the apoptosis-related proteins (TP53, TNF, NFκB1, BCL2). In cellular experiments using DHT-induced KGN cells, PH treatment promoted proliferation, reduced oxidative stress, and suppressed apoptosis compared to the DHT only control. Mechanistically, these effects involved the modulation of sex hormone- and apoptosis-related pathways. In conclusion, this multi-method study demonstrates that PH can mitigate PCOS progression by regulating central pathways linked to hormonal balance and apoptosis, providing a theoretical basis for future preclinical in vivo studies and further investigation into potential clinical applications.
SN - 2045-2322
ER -